Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protection against nephropathy in diabetes with atorvastatin

Trial Profile

Protection against nephropathy in diabetes with atorvastatin

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PANDA
  • Most Recent Events

    • 19 Mar 2014 Accrual to date is 98% according to United Kingdom Clinical Research Network record.
    • 17 Aug 2013 Accrual to date is 98% according to United Kingdom Clinical Research Network record.
    • 15 Mar 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top